Saturday 17 October 2026
Export DMAC’s income statement to Excel — free account
DiaMedica Therapeutics, Inc.
DMAC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 5.56%, free cash flow fell 6.75% and total debt fell 90.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.57
0.47
−5.85%
Follow DMAC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(64.12%) | (67.68%) | (86.47%) | (114.62%) | |
| (58.27%) | (60.84%) | (76.38%) | (98.18%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(62.47%) | (58.89%) | (75.07%) | (99.17%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.56) | (0.62) | (0.58) | (0.59) | |
Free Cash Flow |
(27.77) | (29.10) | (31.03) | (31.54) | |
Capital Expenditures |
(0.04) | (0.04) | (0.04) | (0.03) | |
| Other line items | |||||
Cash ROIC |
(25.97%) | (25.09%) | (31.48%) | (38.54%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.89 | 0.88 | 0.84 | |
Depreciation/Fixed assets |
(6.51) | (6.20) | (5.83) | (6.08) | |
Capex/Depreciation |
0.04 | 0.04 | 0.04 | 0.04 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.56) | (0.62) | (0.58) | (0.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates